Skip to content
The National Bureau of Economic Research said Monday that the COVID-19 crisis has officially launched the U.S. economy into a recession, thus ending the longest economic expansion on record....
Global economies have started reopening, yet the battle against COVID-19 wages on. Researchers and healthcare organizations are racing to develop a vaccine capable of preventing COVID-19 infections, and Wall Street is speculating as to who will emerge victorious.To this end, investor focus has locked in on Inovio Pharmaceuticals (INO). On June 4, Inovio, the International Vaccine Institute (IVI) and Seoul National University (SNU) Hospital announced they would collaborate on the initiation of a Phase 1/2 trial of INO’s COVID-19 DNA vaccine, INO-4800, in South Korea later this month. This will mark the country’s first COVID-19 vaccine clinical study, with it being funded by the Coalition for Epidemic Preparedness Innovations (CEPI) through INO, and supported by both the Korea Center for Disease Control and Prevention of Korea National Institute of Health.Taking a closer look at the study’s design, it is broken down into two stages. These include the evaluation of the candidate’s...
Initial visitors to Sin City following coronavirus shutdowns may feel like they hit a jackpot before they even board a plane. Some Las Vegas casino resorts reopened last week after Nevada lifted coronavirus restrictions that had been in place since late March. Travelers looking to book a room were greeted by an array of deals […]...
Diamond Hill Capital recently released its Q1 2020 Investor Letter, a copy of which you can download below. The Diamond Hill Small Cap Fund posted a return of -36.17% for the quarter, underperforming its benchmark, the Russell 2000 Index which returned -30.61% in the same quarter. You should check out Diamond Hill Capital's top 5 […]...
Will a single antibody be enough to stomp out a COVID-19 infection? Sorrento Therapeutics (SRNE) says no. Rather, the company believes that an antibody cocktail could be capable of providing protection against a SARS-CoV-2 coronavirus infection, with the cocktail remaining effective should the virus mutate.To find the select few with the ability to block the S1 protein's interaction with human angiotensin-converting enzyme 2 (ACE2), the receptor used for viral entrance into human cells, SRNE assessed billions of antibodies. Now, after announcing yet another monoclonal antibody (MaB), STI-4938 (COVIDTRAP), was able to inhibit SARS-CoV-2 viral infection in vitro, some members of the Street think SRNE has what it takes to provide a weapon against the deadly virus.Dawson James analyst Jason Kolbert is standing squarely in the bull camp. He points out that COVIDTRAP, an ACE2-Fc decoy protein, binds firmly to the SARS-CoV-2 virus’ spike protein, with SRNE already getting encouraging feedback from...
TD Ameritrade Trader Strategy Manager Shawn Cruz joins Yahoo Finance’s On The Move to address what stocks investors are buying amid market volatility....
